Vancomycin- and erythromycin-induced hearing loss in humans

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1989-06-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1128/AAC.33.6.791PMID 2669623PMCID PMC284231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The influence of ototoxic drugs on brainstem auditory evoked potentials in man

  2004cited by this paper
• Irreversible sensorineural hearing loss due to erythromycin.

  1988cited by this paper
• Bilateral sensorineural hearing loss associated with mycoplasma pneumoniae infection

  1987cited by this paper
• Auditory brainstem response in young burn-wound patients treated with ototoxic drugs.

  1986cited by this paper
• Vancomycin enhancement of experimental tobramycin nephrotoxicity

  1986cited by this paper
• Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction.

  1986cited by this paper
• Irreversible ototoxic effect of erythromycin.

  1986cited by this paper
• Aminoglycoside ototoxicity.

  1986cited by this paper
• A prospective study of adverse reactions associated with vancomycin therapy.

  1985cited by this paper
• Vancomycin toxicity: a prospective study.

  1985cited by this paper
• Pediatric applications of serial auditory brainstem and middle-latency evoked response recordings.

  1985cited by this paper
• Ototoxicity: a contemporary review of aminoglycosides, loop diuretics, acetylsalicylic acid, quinine, erythromycin, and cisplatinum.

  1985cited by this paper
• [Ototoxic potential of erythromycin].

  1984cited by this paper
• [Reversible hearing loss and erythromycin].

  1984cited by this paper
• Relationship of vancomycin concentrations and ototoxicity.

  1984cited by this paper
• Erythromycin Ototoxicity: Analysis and Conclusions Based on 22 Case Reports

  1984cited by this paper
• [Cochlear toxicity of erythromycin in elderly patients].

  1984cited by this paper
• Vancomycin ototoxicity in patients with normal renal function.

  1984cited by this paper
• Ototoxic effect of erythromycin therapy.

  1984cited by this paper
• Erythromycin-induced ototoxicity.

  1983cited by this paper
• Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

  1983cited by this paper
• Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia.

  1983cited by this paper
• Animal Models of Aminoglycoside Antibiotic Ototoxicity

  1983cited by this paper
• Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis.

  1983cited by this paper
• The ototoxic interaction of viomycin, capreomycin and polymyxin B with ethacrynic acid.

  1982cited by this paper
• Vancomycin: a reappraisal.

  1982cited by this paper
• Erythromycin ototoxicity.

  1982cited by this paper
• Erythromycin-induced ototoxicity substantiated by rechallenge.

  1982cited by this paper
• Vancomycin: a reappraisal.

  1982cited by this paper
• Clinical problems in otitis media and innovations in surgical otology

  1982cited by this paper
• Vancomycin Ototoxicity in patient with normal renal function.

  1981cited by this paper
• Correction to Erythromycin Ototoxicity

  1981cited by this paper
• Psychiatric complications with erythromycin.

  1981influential reference
• Introduction to vancomycin.

  1981cited by this paper
• Ototoxicity of erythromycin gluceptate.

  1981cited by this paper
• Ototoxicity of erythromycin in peritoneal dialysis patients.

  1981cited by this paper
• Structural features of vancomycin.

  1981cited by this paper
• Aminoglycoside Antibiotics in the Treatment of Otologic Infections

  1981cited by this paper
• Comparative Ototoxicity of Bumetanide and Furosemide when Used in Combination with Kanamycin

  1981cited by this paper
• Ototoxicity resulting from the combined administration of potent diuretics and other agents.

  1981cited by this paper
• Legionnaires' disease: unusual clinical and laboratory features.

  1980cited by this paper
• Erythromycin ototoxicity.

  1980cited by this paper
• [Erythromycin ototoxicity in patients with renal insufficiency (author's transl)].

  1980cited by this paper
• Probable Erythromycin Ototoxicity

  1980cited by this paper
• Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid.

  1979cited by this paper
• Ototoxicity of erythromycin in patients with renal insufficiency.

  1979cited by this paper
• [Transient deafness in patients with renal insufficiency treated with erythromycin].

  1979cited by this paper
• Ototoxicity of erythromycin lactobionate.

  1979cited by this paper
• Vancomycin therapy of bacterial endocarditis.

  1978cited by this paper
• ‘VANCOMYCIN REVISITED’

  1978cited by this paper
• Ototoxicity of erythromycin.

  1978cited by this paper
• Ototoxicity of erythromycin.

  1978cited by this paper
• Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report.

  1978cited by this paper
• Reversible Sensorineural Hearing Loss with Intravenous Erythromycin Lactobionate

  1977cited by this paper
• Vancomycin. A second look.

  1977cited by this paper
• Letter: Partial deafness after erythromycin.

  1975cited by this paper
• Transient perceptive deafness due to erythromycin lactobionate.

  1973cited by this paper
• Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application.

  1973cited by this paper
• Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis.

  1971cited by this paper
• Hearing aids for the elderly.

  1971cited by this paper
• Kanamycin Ototoxicity—Possible Potentiation by Other Drugs

  1970cited by this paper
• The treatment of severe staphylococcal infections with vancomycin.

  1961cited by this paper
• Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases.

  1960cited by this paper
• Comparative Clinical Effectiveness and Toxicity of Vancomycin, Ristocetin, and Kanamycin

  1960cited by this paper
• Vancomycin: Report on Treatment of Patients with Severe Staphylococcal Infections

  1959cited by this paper
• Anaphylactoid reaction to vancomycin.

  1959influential reference
• Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report.

  1958cited by this paper

• Recent Trends in Therapeutic Drug Monitoring of Peptide Antibiotics.

  2024cites this paper
• Ototoxicity of Non-aminoglycoside Antibiotics

  2021cites this paper
• The antibiotic vancomycin induces complexation and aggregation of gastrointestinal and submaxillary mucins

  2020cites this paper
• Ototoxicity and Nephrotoxicity With Elevated Serum Concentrations Following Vancomycin Overdose: A Retrospective Case Series.

  2019cites this paper
• Analysis of drug-induced hearing loss by using a spontaneous reporting system database

  2019cites this paper
• Vancomycin and its crystalline degradation products released from bone grafts and different types of bone cement

  2019cites this paper
• Long-term vancomycin use had low risk of ototoxicity

  2019cites this paper
• ASHP Therapeutic Position Statements 685 Therapeutic Monitoring of Vancomycin in Adult Patients : A Consensus Review of the American Society of HealthSystem Pharmacists

  2018cites this paper
• Role of Chemical Entities in Ototoxicity

  2018cites this paper
• Drug‐induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies

  2017cites this paper
• Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy

  2017cites this paper
• Médicaments ototoxiques et oculotoxiques : la vigilance du pharmacien

  2016cites this paper
• Vancomycin toxicity in neonates: a review of the evidence

  2016cites this paper
• A Re view of An ti bi otic-In duced Ototoxicity

  2016cites this paper
• Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

  2013cites this paper
• Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

  2013cites this paper
• Economic Aspects of Antibacterial Adverse Effects

  2012cites this paper
• Isolation and characterization of compounds from Podocarpus henkelii (Podocarpaceae) with activity against bacterial, fungal and viral pathogens

  2012cites this paper
• Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

  2011cites this paper
• Unique Aspects of Content Unique Aspects of Software

  2010cites this paper
• Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind

  2010cites this paper
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

  2009cites this paper
• Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review.

  2009cites this paper
• Audiometric changes in patients undergoing liver transplantation using distinct immunosuppressive protocols

  2008cites this paper
• Vancomycin: Understanding Its Past and Preserving Its Future

  2008cites this paper
• Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses

  2008cites this paper
• Understanding drug ototoxicity: molecular insights for prevention and clinical management

  2006cites this paper
• Vancomycin: a history.

  2006cites this paper
• The pharmacokinetic and pharmacodynamic properties of vancomycin.

  2006cites this paper
• West Nile Virus infection with hearing loss.

  2006cites this paper
• Aetiological Causes Of Reversible Sensorineural Hearing Loss

  2005cites this paper
• Nutzen-Risiko-Abwägung bei Antiinfektiva aus der Sicht der Zulassungsbehörde

  2005cites this paper
• Vancomicina, estudo de utilizacao com enfase em suas reacoes adversas

  2005cites this paper
• Large vancomycin overdose in two premature infants with minimal toxicity.

  2004cites this paper
• Large Vancomycin Overdose in Two Premature Infants with Minimal Toxicity

  2004cites this paper
• Chapter 8 – Rationale and utility of therapeutic drug monitoring for the optimization of antibiotic therapy

  2004cites this paper
• Experimental, clinical and preventive aspects of ototoxicity

  2004cites this paper
• Delirium in the elderly resulting from azithromycin therapy.

  2003cites this paper
• Sensorineural Hearing Loss Associated with Intrathecal Vancomycin

  2003cites this paper
• Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic.

  2003cites this paper
• Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs

  2001cites this paper
• Comparative Safety of Teicoplanin and Vancomycin

  2000cites this paper
• Work-related noise hazards in the dental surgery.

  2000cites this paper
• Erythromycin-Induced Ototoxicity: A Case Report and Review of the Literature

  2000cites this paper
• Gentamicin for the practicing urologist: review of efficacy, single daily dosing and "switch" therapy.

  2000cites this paper
• Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments

  1999cites this paper
• Hearing loss in critical care: an unappreciated phenomenon.

  1999cites this paper
• Symposium on antimicrobial agents--Part XII. Vancomycin.

  1999cites this paper
• Intravenous Azithromycin‐Induced Ototoxicity

  1999cites this paper
• Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry.

  1998cites this paper
• Aminoglycosides, vancomycin, and quinolones.

  1998cites this paper
• Septicemia and Septic Shock in Pediatric Patients: 140 Consecutive Cases on a Pediatric Hematology‐Oncology Service

  1998cites this paper
• Laboratory guidelines for monitoring of antimicrobial drugs

  1998cites this paper
• Comparative safety of teicoplanin and vancomycin.

  1998cites this paper
• Drug Administration in Patients with Renal Insufficiency

  1997cites this paper
• Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease.

  1997cites this paper
• Efficacy of vancomycin/tri-iododecyclemethyl ammonium chloride-coated ventriculostomy catheters in reducing infection.

  1997cites this paper
• Cystic fibrosis pulmonary infections

  1996cites this paper
• Mania due to clarithromycin therapy in a patient who was not infected with human immunodeficiency virus.

  1996cites this paper
• Pharmacodynamics of antimicrobial therapy in surgery.

  1996cites this paper
• Ototoxicity: Of Mice and Men

  1996cites this paper
• Macrolide Antibiotics in Paediatric Infectious Diseases

  1996cites this paper
• Lack of effect of vancomycin and gentamicin on auditory function in guinea pigs

  1996cites this paper
• [Therapy with antibiotics in renal failure].

  1996cites this paper
• Drug-Induced Tinnitus and Other Hearing Disorders

  1996cites this paper
• Effect of erythromycin on the auditory evoked responses in rats

  1996cites this paper
• Injectable medications for hemodialysis patients.

  1996cites this paper
• Pharmacodynamics of Antimicrobial Therapy

  1996cites this paper
• The Effect of Erythromycin on Cochlear Potentials.

  1996cites this paper
• Teicoplanin or vancomycin in the treatment of Gram–positive infections?

  1995cites this paper
• Myths of dental-induced prosthetic joint infections.

  1995cites this paper
• Antibiotic therapy and the anesthesiologist.

  1995cites this paper
• Rationalization of Vancomycin Serum Concentration Monitoring

  1995cites this paper
• Formulary Management of Macrolide Antibiotics

  1995cites this paper
• Therapeutisches Drug Monitoring

  1995cites this paper
• Myths of Dental-Induced Endocarditis-Reply

  1994cites this paper
• Monitoring serum vancomycin levels: climbing the mountain because it is there?

  1994cites this paper
• Serum vancomycin concentrations: reappraisal of their clinical value.

  1994cites this paper
• Hearing loss.

  1994cites this paper
• Erythromycin ototoxicity in liver transplant patients

  1994cites this paper
• Vancomycin toxicity. What is the evidence for dose dependency?

  1994cites this paper
• Hearing loss.

  1994cites this paper
• Use of Angiotensin-Converting Enzyme Inhibitors in Heart Failure

  1994cites this paper
• The challenge of sensorineural hearing loss in rheumatoid arthritis.

  1994cites this paper
• Is Vancomycin Ototoxic?

  1993cites this paper
• In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci

  1993cites this paper
• Ototoxicity of erythromycin in man: electrophysiologic approach.

  1993cites this paper
• Erythromycin-Induced Hypoacusis: 11 New Cases and Literature Review

  1993cites this paper
• Vancomycin intoxication in a preterm neonate

  1993cites this paper
• Semi-synthetic derivatives of erythromycin.

  1993cites this paper
• Vancomycin Administration into the Cerebrospinal Fluid: A Review

  1993cites this paper
• Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin.

  1993cites this paper
• Ototoxicity of vancomycin and analogues.

  1993cites this paper
• Oral Bicarbonate Supplements in Dialysis Patients

  1993cites this paper
• Adverse Effects of Macrolide Antibacterials

  1993cites this paper
• Prospective Assessment of Nephrotoxicity with Concomitant Aminoglycoside and Vancomycin Therapy

  1993cites this paper
• InVitro Activities ofRamoplanin, Selected Glycopeptides, Fluoroquinolones, andOtherAntibiotics against Clinical Bloodstream Isolates ofGram-Positive Cocci

  1993cites this paper
• Severe endophthalmitis after neonatal skin lesions with positive cultures ofAspergillus fumigatus

  1993cites this paper
• Diagnostic difficulties and positive therapeutic response in a patient with sinus histiocytosis with massive lymphadenopathy

  1993cites this paper
• Ototoxic liability of erythromycin and analogues.

  1993cites this paper